De-sheng S. Weng
School Of Biomedical Engineering//Guangdong Provincial Key Laboratory Of Medical Image Processing//Guangdong Provincial Engineering Laboratory For Medical Imaging And Diagnostic Technology
Guangzhou, 510515, China
Guangzhou, 510515, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.
Journal: Signal transduction and targeted therapy
Published: July 30, 2024
Automatic classification of immune-mediated glomerular diseases based on multi-modal multi-instance learning
Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University
Published: April 10, 2024
A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors.
Journal: ESMO open
Published: March 06, 2024
Correction: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.
Journal: Journal of hematology & oncology
Published: November 05, 2023
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: September 11, 2023
New nomograms to predict overall and cancer-specific survival of angiosarcoma.
Journal: Cancer medicine
Published: July 17, 2021
Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma.
Journal: Cancer chemotherapy and pharmacology
Published: July 05, 2021
Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
Journal: Journal for immunotherapy of cancer
Published: December 29, 2020
The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study.
Journal: Clinical & translational immunology
Published: October 15, 2020
Screening and identification of hub genes in bladder cancer by bioinformatics analysis and KIF11 is a potential prognostic biomarker.
Journal: Oncology letters
Published: July 31, 2020
Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma.
Journal: International immunopharmacology
Published: July 16, 2020
Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study.
Journal: Frontiers in oncology
Published: July 13, 2020
Last Updated: 09/26/2026